These 10 Firms Dominated Last Week’s Rally

3. ImmunityBio Inc. (NASDAQ:IBRX)

ImmunityBio Inc. (IBRX) saw a surge in its share prices last week, closing higher by 21.49 percent at $2.94 apiece as investors resorted to bargain-hunting after touching a 52-week low the week prior.

Earlier this week, the company announced plans to submit multiple treatments for approval by the Food and Drug Administration in 2025. It said it would submit a supplemental biologics license application (BLA) for the treatment of bladder cancer. If approved by the FDA, the BLAs will allow the company to sell its products across the US.

In addition, it would also submit another BLA for the treatment of patients with a certain type of lung cancer.

ImmunityBio Inc. (IBRX) said that a Phase 2B study had already indicated positive results for patients whose first and second treatment attempts ended unsuccessfully after using the company’s Anktiva drug in combination with other inhibitors.